最終更新日：2025/11/20
The clinical trial evaluated the safety and tumor-targeting efficacy of 90Y-DOTA-biotin in patients with recurrent ovarian cancer.
正解を見る
The clinical trial evaluated the safety and tumor-targeting efficacy of 90Y-DOTA-biotin in patients with recurrent ovarian cancer.
音声機能が動作しない場合はこちらをご確認ください
編集履歴（0）
